Solute carrier family protein (SLC)

The solute carrier (SLC) family represents the largest group of membrane transport proteins in the human genome, comprising over 400 members organized into 65 families (Hediger et al., 2013, Molecular Aspects of Medicine). These proteins facilitate the movement of a diverse array of substrates across cellular membranes, including inorganic ions, nucleotides, amino acids, lipids, and drugs, typically through facilitated diffusion or secondary active transport (IUPHAR/BPS Guide to Pharmacology). Because SLC transporters play critical roles in physiological processes such as nutrient uptake and waste removal, they are significant therapeutic targets and key determinants of drug pharmacokinetics (UniProt Consortium). However, the term "Unspecified solute carrier family protein" is considered an insufficiently specific target designation for drug development or clinical annotation, as therapeutic efficacy and safety are highly dependent on the specific SLC isoform being modulated (SLC Tables, bioparadigms.org). Mutations or dysregulation of various SLC members are linked to numerous pathologies, including metabolic syndromes, neurodegenerative disorders, and various forms of cancer (PubMed, PMID: 23506860). In a drug discovery context, identifying the specific family member (e.g., SLC6A3 for the dopamine transporter) is essential for understanding the mechanism of action and potential side effect profile.

Other names

SLC transportersSolute carrier seriesMembrane transport proteinsSLC superfamily

Inhibition of solute transport across biological membranes, competition with endogenous substrates for transport binding sites, or modulation of electrochemical gradients to alter substrate flux (IUPHAR/BPS Guide to Pharmacology).